It is used as a treatment for patients over 6 years of age with moderate severe allergic asthma (SAA), with serum IgE levels of 30–1300 IU/mL in the United States, or with SAA with serum IgE levels of 30–1500 IU/mL in Europe (Table 3). Here, IGHE is linked to severe aplastic anemia.